FDA Panel Casts SSRIs During Pregnancy as Risky—Many Experts Disagree

Lars Schneider

doi:10.1001/jama.2025.14105

August 15, 2025JAMA

FDA Panel Casts SSRIs During Pregnancy as Risky—Many Experts Disagree

View at Publisher

Ask AI

Bookmark

Share

Key Points

SSRIs are deemed risky during pregnancy, according to an FDA panel, yet many specialists argue against this view.
The panel's conclusions may influence treatment options for pregnant individuals, contributing to an ongoing debate.
Expert disagreement on antidepressant safety in pregnancy raises questions about patient care and medication guidelines.
The FDA's stance on SSRIs could lead to more scrutiny on prescribing practices and further investigations.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Recent FDA panel highlights risks of antidepressant use during pregnancy, suggesting differing expert opinions.

Abstract

This Medical News article discusses claims about antidepressant treatment during pregnancy presented at a recent panel organized by the US Food and Drug Administration.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lars Schneider (2025) studied this question.

synapsesocial.com/papers/68c19f9154b1d3bfb60dafaa https://doi.org/10.1001/jama.2025.14105

View at Publisher

Ask AI

Bookmark

Share

FDA Panel Casts SSRIs During Pregnancy as Risky—Many Experts Disagree

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

FDA Panel Casts SSRIs During Pregnancy as Risky—Many Experts Disagree

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading